Cargando…
Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine
A review. Development of pharmaceutical antagonists of transient receptor potential melastatin 8 (TRPM8) have been pursued for the treatment of chronic pain and migraine. This review focuses on the current state of this progress.
Autores principales: | Weyer, Andy D., Lehto, Sonya G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490394/ https://www.ncbi.nlm.nih.gov/pubmed/28358322 http://dx.doi.org/10.3390/ph10020037 |
Ejemplares similares
-
AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia
por: Lehto, Sonya G., et al.
Publicado: (2015) -
TRPM8 genetic variant is associated with chronic migraine and allodynia
por: Ling, Yu-Hsiang, et al.
Publicado: (2019) -
Transient receptor potential melastatin 8 (TRPM8) channels are involved in body temperature regulation
por: Gavva, Narender R, et al.
Publicado: (2012) -
Therapeutic potential of TRPM8 antagonists in prostate cancer
por: Di Donato, Marzia, et al.
Publicado: (2021) -
Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans
por: Gavva, Narender R., et al.
Publicado: (2019)